NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 78.43 percentage) |
(Changed an Item: Import item from Portugal) |
||||||||||
| Property / budget | Property / budget | ||||||||||
| 1,136,307.6 Euro
| ||||||||||
| Property / EU contribution | Property / EU contribution | ||||||||||
| 891,220.51 Euro
| ||||||||||
| Property / priority axis | |||||||||||
| Property / priority axis: Strengthening research, technological development and innovation (OT1) / rank | |||||||||||
Normal rank | |||||||||||
| Property / co-financing rate | |||||||||||
78.43 percent
| |||||||||||
| Property / co-financing rate: 78.43 percent / rank | |||||||||||
Normal rank | |||||||||||
Revision as of 11:51, 5 November 2022
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,220.51 Euro
0 references
1,136,307.6 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references